drug
icotrokinra hydrochloride
Marketedupdated 5mo agoby $JNJ JOHNSON & JOHNSON
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4indications
investigational
IBD (Crohn's + UC)
all catalysts(1)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 12, 2039
~12.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Nov 19, 2041formulationUS 11939361
- Jan 14, 2041compositionUS 11845808
- Jul 12, 2039compositionUS 12552836
News(4)
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 6d ago
- 5 biotechs braving the commercial waters with product launchesA growing number of biotechs are entering the market with newly launched medicines, a pattern indicative of “improving capital markets,” according to Jefferies’ Andrew Tsai.biospace · 18d ago
- J&J touts Icotyde prescriptions, but not sales, in first full quarterJohnson & Johnson teased some details on Wednesday morning about how the launch of its expected blockbuster Icotyde performed in the second quarter. Without disclosing how much revenue the plaque p…endpoints · 2mo ago
- Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pillSet to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.biopharma_dive · 2mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that